Global Genomics Group (G3) Announces Completion of Enrollment in GLOBAL Study with 7,500 Patients - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Global Genomics Group (G3) Announces Completion of Enrollment in GLOBAL Study with 7,500 Patients Single Largest Prospective Pan-Omic Study to Identify Key Biomarkers and Central Therapeutic Targets for Cardiovascular Diseases Has Completed Enrollment


Global Genomics Group (G3) Announces Completion of Enrollment in GLOBAL Study with 7,500 Patients

Single Largest Prospective Pan-Omic Study to Identify Key Biomarkers and Central Therapeutic Targets for Cardiovascular Diseases Has Completed Enrollment

PR Newswire

RICHMOND, Va., May 27, 2014 /PRNewswire/ -- Global Genomics Group (G3), a life sciences company investigating biological networks that lead to the development of disease, today announced that it has completed the enrollment of patients in its international, prospective GLOBAL (Genetic LOci and Burden of Atherosclerotic Lesions) study, months ahead of schedule. GLOBAL is the first pan-omic study designed to identify disease-related pathways, new drug targets and biomarkers for cardiovascular diseases such as atherosclerosis.

"The early completion of the GLOBAL study is a significant milestone for G3 and confirms the strong support and interest from the medical community," said Tonya Mallory, chief executive officer, president and co-founder of Health Diagnostic Laboratory, a strategic partner of G3. "G3 is in the process of analyzing the initial data and could have pilot data results as early as the first half of 2015. The study will analyze 22 trillion data points from 7,500 patients and will enable us to gain an in-depth understanding of the biological basis behind the complex processes responsible for atherosclerosis, leading to the identification of new biomarkers for early detection and new targets for the development of novel and effective drugs. As of today, only 20 drug candidates are being developed for atherosclerosis and coronary artery disease, the leading cause of death worldwide."

John Lesser, M.D., one of the principal investigators for the GLOBAL study and former president of the Society of Cardiovascular Computed Tomography, said, "Early disease detection and intervention, as well as effective therapeutic options, remain significant unmet medical needs in cardiovascular disease.  It is quite remarkable to see such a large scale, comprehensive study executed so quickly. I am thrilled to be a part of this work, and I am looking forward to the potential of using the clinical diagnostic tests that result."

The GLOBAL study completed the enrollment of 7,500 patients at 48 clinical sites in North America, Europe, and Australia. For more information about this study, please visit www.globalgenomicsgroup.com.

About GLOBAL

GLOBAL is the largest pan-omic study combining whole genome sequencing, whole genome methylation, whole transcriptome sequencing, unbiased proteomics, metabolomics and lipidomics with coronary computed tomographic (CT) angiography, an advanced imaging technology for phenotyping, which allows the precise classification of disease in patients.

The ongoing GLOBAL study (ClincialTrials.gov Identifier NCT01738828) is an international, prospective, multi-center study recruiting up to 10,000 patients to characterize novel disease networks and biomarkers for coronary artery disease (CAD). The study is being funded by G3 and conducted together with strategic partner, Health Diagnostic Laboratory. Eligible patients undergo coronary CT angiography providing an accurate and detailed examination of the disease and disease status. This precision phenotyping is combined with a pan-omic analysis, and the data is then analyzed utilizing specifically-developed systems biology-based bioinformatics technology for identification of diagnostic biomarkers and potential therapeutic targets.

About Global Genomics Group (G3)
G3 is a life sciences company investigating biological networks that lead to the development of disease to identify novel biomarkers and therapeutic targets. G3 combines precision phenotyping with pan-omics (genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics and lipoprotein proteomics) and bioinformatics to investigate the development and progression of conditions such as atherosclerosis in cardiovascular disease.

For additional information, please visit www.globalgenomicsgroup.com.

G3 Contacts
Media
Martina Schwarzkopf, Ph.D.
(212) 845-4292
martina.schwarzkopf@russopartnersllc.com

Corporate
Idean Marvasty
(404) 368-1554
idean.marvasty@globalgenomicsgroup.com

SOURCE Global Genomics Group (G3)

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
7%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here